1. 1.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. 2.Van Der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol. 2010;101(3):259-69. 3.Radmard AR. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143-6. 4.Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68(23):3853-68. 5.Nosrati A, Naghshvar F, Torabizadeh Z, Salehi F. Correlation of Colorectal cancer stem cell marker CD24 expression with clinicopathologic features and survival of patients with colorectal cancer. Govaresh. 2014;19(2):86-94. 6.Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14(17):2123-33. 7.Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007;39(8):733-9. 8.Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, et al. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2006;28(5):247-52. 9.GUZIŃSKA-USTYMOWICZ K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res. 2006;26(2B):1589-94. 10.Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012;50(1):12-9. 11.Langenskiöld M, Holmdahl L, Falk P, Ivarsson M-L. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2005;20(3):245-52. 12.Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2012;19(1):318-25. 13.Koskensalo S, Hagström J, Linder N, Lundin M, Sorsa T, Louhimo J, et al. Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer. BMC Clin Pathol. 2012;12(1):24. 14.Li C-Y, Yuan P, Lin S-S, Song C-F, Guan W-Y, Yuan L, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biology. 2013;34(2):735-41. 15.Jensen SA, Vainer B, Bartels A, Brünner N, Sørensen JB. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells–associations with histopathology and patients outcome. Eur J Cancer. 2010;46(18):3233-42. 16.Yang B, Tang F, Zhang B, Zhao Y, Feng J, Rao Z. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World J Surg Oncol. 2014;12(1):24. 17.Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjänen S, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer. 2009;40(3-4):91-7. 18.Liabakk N-B, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56(1):190-6. 19.Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, et al. p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem. 2010;285(20):15149-58. 20.Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011;71(3):998-1008. 21.Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969-80. e3. 22.Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 2010;70(2):792-801. 23.Choi D, Lee HW, Hur KY, Kim JJ, Park G-S, Jang S-H, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World journal of gastroenterology: WJG. 2009;15(18):2258. 24.THIS I, editor Surgical Pathology of Carcinoma of the Colon and Rectum. Semin Oncol; 1991. 25.Mohiuddin M, Ahmed MM, editors. Critical issues in the evolving management of rectal cancer. Semin Oncol; 1997. 26.Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell P, et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer. 2011;104(3):480-7. 27.Kemper K. Molecular identification and targeting of colorectal cancer stem cells2012. 28.Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229-34. 29.Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ. 2010;340. 30.Fidler IJ. The pathogenesis of cancer metastasis: the'seed and soil'hypothesis revisited. Nature Reviews Cancer. 2003;3(6):453-8. 31.Westermarck J, KÄHÄRI V-M. Regulation of matrix metalloproteinase expression in tumor invasion. The FASEB Journal. 1999;13(8):781-92. 32.Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 1992;7:120-. 33.Wilson PM, LaBonte MJ, Lenz H-J. Molecular markers in the treatment of metastatic colorectal cancer. The Cancer Journal. 2010;16(3):262-72. 34.Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM. Resident stromal cell‐derived MMP‐9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer. 2007;121(3):495-500.